AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE Randomized, Controlled Trial
8.8.2023 16:30:00 EEST | Business Wire | Press release
AgNovos Bioscience, a medical technology company working to transform the treatment of bone disease by addressing persistent unmet needs in the care of patients, announced today that it has enrolled the 150th patient in the clinical study titled “Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures” (RESTORE). RESTORE is a randomized, controlled, prospective, single-blinded, global study designed to evaluate whether women undergoing surgical repair of a fragility hip fracture, and treated contralaterally with the AGN1 LOEP kit, are at reduced risk of a second hip fracture. The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria. RESTORE is expected to include more than 50 study sites and enroll at least 650 patients.
“The initiation of RESTORE and the enrollment of the 150th patient is a major milestone for the Company,” explained James Pilachowski, Senior Vice President of Hip Program. “RESTORE will be one of the largest prospective orthopaedic trauma studies ever conducted. The data generated will be critical to our efforts to gain access to new markets, including the U.S. and Japan.”
To ensure strategic study oversight and guidance, AgNovos Bioscience, Inc. has chartered a global steering committee comprised of experts in orthopaedics, trauma, metabolic bone health, internal medicine and medical ethics. The committee is co-chaired by Dr. Serge Ferrari, head of the Clinical Service and Research Laboratory of Bone Diseases at the Geneva University Hospital (Switzerland) and Dr. Paul Tornetta, director of the Orthopaedic Trauma department at Boston Medical Center (USA).
Dr. Tornetta shared his perspective on the importance of the study: “We all know that fragility hip fractures will be one of the biggest challenges facing orthopaedic surgeons over the next 10-20 years. Addressing contralateral hip fracture risk will be key to meeting that challenge. The science and research supporting this treatment is positive. I am glad the study is underway; I think that it could make a real difference.”
Dr. Ferrari noted that “pharmacological approaches to treatment of osteoporosis are very important but are not sufficient by themselves to solve the challenge of secondary fracture risk, especially in patients with recent fractures. The incremental risk of fracture for these patients is highest during the first year following the index fracture. If this study is successful, orthopaedic surgeons will have an important new role to play in our efforts to reduce secondary hip fracture risk.”
More than two million hip fragility fractures occur globally every year. Hip fragility fractures result from low-energy trauma such as a fall from standing height or less. These fractures are associated with significant morbidity and mortality, and often create significant burden for affected individuals, families and healthcare systems. Although multiple factors contribute to hip fracture risk, a key factor is osteoporosis and related bone loss and fragility.
“One of the reasons hip fragility fractures are so devastating is that individuals suffering one fracture are at increased risk for a second,” explained Dr. James Howe, the Co-Founder and Chief Medical Officer of AgNovos Bioscience, Inc. “The outcomes of second fractures are often even worse than those of the first. I saw this pattern during my decades of clinical practice in orthopaedics. I look forward to reviewing the data generated by RESTORE with other clinicians and organizations committed to addressing secondary hip fracture risk.”
About the AGN1 LOEP Kit
The AGN1 LOEP Kit contains the instruments and materials to perform a minimally invasive procedure to implant AGN1, a proprietary, calcium-based, osteoconductive, and tri-phasic implant material. AGN1 is uniquely formulated with a cell-friendly surface architecture and a resorption profile that enables the rapid formation of new bone. Clinical research has shown that AGN1 LOEP treatment delivers rapid, substantial and durable increase in the strength of osteoporotic femurs. The kit is available in Europe under the brand name OSSURE™ LOEP kit.
About AgNovos Bioscience, Inc.
AgNovos Bioscience, Inc. is a medical technology company developing new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. AgNovos Bioscience, Inc. is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD. www.agnovos.com
CAUTION The OSSURE (LOEP) kit is not cleared for use in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808554123/en/
Contact information
Jason Foley
Associate Vice President, Spine Program and Marketing
+1 332-910-7332
jfoley@agnovos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 16:45:00 EET | Press release
We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live
Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 16:39:00 EET | Press release
Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real capacity. Factbird is a System of Action, built for manufacturers who have plenty of data and struggle to act on it. It connects production data from every line, machine, and operator
Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release
Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i
NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 16:08:00 EET | Press release
NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115196647/en/ NIKE, Inc. is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. Elite marathoners. Backyard hoopers. An athlete* walking into the gym for the first time. Every athlete NIKE, Inc. works alongside pushes the company to imagine what doesn’t yet exist, then make those possibilities real. Today, NIKE, Inc. is showing what comes next. As part of its World of Athletes* showcase in Beaverton, Ore., the company is unveiling Tuned Air, the next frontier of Nike Air; new Nike Mind and Nike Free footwear, platforms built to scale across sport; innovation
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release
Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
